Reliable wound care manufacturing for distributors, importers, procurement organisations, and healthcare suppliers across established and emerging European markets.
As a healthcare products supplier for Europe, Meghdoot Pharma supports distributors, importers, and healthcare organisations with CE-certified wound care products for professional healthcare markets.
The European wound care management market is valued at approximately USD 4.88 billion (€4.52 billion) in 2026 and is projected to reach USD 6.23 billion (€5.77 billion) by 2031, growing at a 4.99%
CAGR.
Demand is driven by an ageing population, with over 21.6% of Europeans aged 65 years and above, and 65.6 million adults living with diabetes, increasing the need for advanced wound care.
Meghdoot Pharma has been actively supplying its flagship wound dressing product across Portugal, Slovakia, Cyprus, Bulgaria, and the Czech Republic for the past few years. To ensure seamless market adoption and regulatory compliance, our products are packaged and labelled in the respective local languages of each country. The market insights below highlight the growing demand for advanced wound care solutions, reinforcing the significant opportunities for continued expansion across these markets.
Slovakia continues to modernise its healthcare infrastructure through ongoing investment and an ageing population, increasing demand for advanced wound care across hospitals, long-term care facilities, and specialist healthcare providers.
Key market insights:
Advanced wound care remains one of Slovakia's fastest-growing healthcare segments.
Rising diabetes prevalence continues to increase cases of diabetic foot ulcers, pressure ulcers, and chronic wounds.
Hospitals are expanding the use of advanced wound dressings, including foam, hydrocolloid, alginate, and antimicrobial products.
Telemedicine and digital wound monitoring are becoming increasingly important in chronic wound management.
Portugal's wound care market is supported by the Serviço Nacional de Saúde (SNS) alongside an established private healthcare sector. Public procurement and an ageing population continue to influence demand for advanced wound care products.
Key market insights:
More than 22% of Portugal's population is aged 65 years or older.
INFARMED regulates medical devices and oversees market access.
Public hospitals procure wound care products through structured purchasing and reimbursement systems.
Growing cases of diabetic foot ulcers, pressure ulcers, venous leg ulcers, and surgical wounds continue to support demand for advanced wound dressings.
The advanced wound care market is forecast to grow at approximately 4.5%–5.8% CAGR.
The Czech Republic continues to strengthen specialist wound management through dedicated wound care centres and evidence-based clinical practice.
Key market insights:
The wound care market is projected to exceed USD 7.7 million in 2026.
More than 400 specialist wound healing centres provide dedicated treatment for chronic and complex wounds.
Increasing cases of diabetic foot ulcers, venous leg ulcers, pressure ulcers, and surgical wounds continue to drive clinical demand.
Hospitals and specialist clinics continue expanding the use of advanced foam, hydrocolloid, alginate, silicone, and antimicrobial wound dressings.
The introduction of Cyprus' National Health System (GeSY) has significantly expanded access to specialist wound care services across public and private healthcare providers.
Key market insights:
GeSY provides healthcare coverage to more than 90% of residents.
Healthcare expenditure represents approximately 9–10% of GDP, supporting continued healthcare investment.
Around 12–13% of adults are living with diabetes, contributing to growing demand for diabetic wound management.
Cyprus serves as an important healthcare hub connecting Europe, the Middle East, and North Africa.
Advanced wound dressings continue to see increased adoption across hospitals, specialist clinics, and community healthcare services.
Bulgaria's healthcare market continues to expand through increasing adoption of advanced wound care products, supported by an ageing population, rising chronic wound prevalence, and strong reliance on imported medical devices.
Key market insights include:
Bulgaria's medical device market exceeds EUR 300 million, with more than 90% of medical devices supplied through imports.
Approximately 23.8% of the population is aged 65 years or older, increasing demand for chronic wound management.
Rising cases of diabetic foot ulcers, venous leg ulcers, pressure injuries, and surgical wounds continue to support the adoption of advanced wound dressings.
Medical devices are regulated under the EU Medical Device Regulation (EU MDR) together with oversight from the Bulgarian Drug Agency (BDA), supporting quality and regulatory compliance for imported wound care products.
COMPLETE PORTFOLIO
Our export portfolio includes sterile wound care products manufactured for professional healthcare use.
HAVE QUESTIONS?
We manufacture a comprehensive, CE-certified wound care portfolio, including our signature MEGHdin range, designed for professional healthcare markets. Our products are manufactured to meet the strict clinical needs of hospitals, long-term care facilities, and specialist wound care clinics across both established and emerging European regions.
We supply reliable, regulation-compliant wound care manufacturing services to medical device distributors, commercial importers, public procurement organizations, and healthcare suppliers. Our export team is fully equipped to provide custom export quotes and navigate European logistics to support your supply chain.
The European wound care management market is rapidly expanding due to two primary factors: a rapidly aging population (with more than 21% of Europeans aged 65 years and older) and a high prevalence of diabetes, which currently affects over 65 million adults. These shifts have significantly increased the clinical need for advanced dressings to treat complex conditions like diabetic foot ulcers, venous leg ulcers, and chronic pressure injuries.
Procurement pathways vary by region, but regulatory compliance remains foundational. For instance, in Portugal, public hospitals procure wound care through the Serviço Nacional de Saúde (SNS) under INFARMED regulations. In Cyprus, the GeSY national health system now covers more than 90% of residents, greatly expanding patient access to specialist wound care and boosting regional institutional demand.
Yes. All of our wound care products are CE-certified and manufactured to fully comply with the EU Medical Device Regulation (EU MDR). This ensures seamless market entry and strict quality compliance in import-reliant Eastern European markets, such as Bulgaria, where over 90% of medical devices are imported under the oversight of the Bulgarian Drug Agency (BDA), as well as the rapidly modernizing infrastructure of Slovakia and the Czech Republic.
Speak with our export team about CE-certified wound care products for European healthcare
markets.
